Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Novacyt confirms end of Yourgene Taiwan disposal discussions

(Sharecast News) - Novacyt announced on Tuesday that it had received formal notification from INEX Innovate terminating discussions around the acquisition of Yourgene Health Taiwan. The AIM-traded firm noted that Yourgene Health initially announced the acquisition on 13 June 2023.

As a result of the termination, Yourgene's Taiwanese laboratory business would remain within the Novacyt group.

"The board does not consider the divestment material and will continue to evaluate a number of options in relation to the future of the Taiwanese laboratory business that offer the best value to all stakeholders," the Novacyt board said in its statement.

At 1158 GMT, shares in Novacyt were down 5.77% at 47.35p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Goldman Sachs to scrap bonus cap for UK dealmakers
(Sharecast News) - Goldman Sachs will remove a cap on bonuses for its London-based staff, according to Sky News, with the firm now set to resume making multi-million-pound payouts to its top-performing traders and dealmakers.
Gazprom swings to $6.9bn loss as Europe sales plunge
(Sharecast News) - Russia's natural gas heavyweight Gazprom swung to huge loss in 2023 after sales to Europe dropped due to Western sanctions on Moscow.
London cabbies launch £250m legal action against Uber
(Sharecast News) - Uber Technologies is facing legal action on behalf of more than 10,500 London black cab drivers, it was confirmed on Thursday.
Peloton announces CEO departure; to cut 15% of workforce
(Sharecast News) - Peloton announced the departure of its chief executive on Thursday, alongside plans to cut around 15% of its workforce amid a restructuring programme aimed at reducing annual expenses by more than $200m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.